Morningstar

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking ...
Hosted on MSN

Non-contractile heart cells help sustain persistent atrial fibrillation, study reveals

Atrial fibrillation (AF), the most common chronic cardiac arrhythmia in clinical practice, is very challenging to treat once it becomes persistent, after which spontaneous return to normal rhythm ...

Pulse Biosciences, Inc.: Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation

U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary ...